Breast Cancer

Study suggests future interventions targeting improvements in cancer screenings may need to focus on the time of day when a patient visits a doctor.

Using genetic testing for women newly diagnosed with breast cancer can decrease the high cost of chemotherapy use in the first year of care.

The combination of selinexor and 4-OHT may be able to prevent endocrine resistance in hormone-responsive breast cancer by rewiring gene pathways.

Top news of the day from across the health care landscape.

The indication’s expansion for palbociclib to include male patients is based upon data from postmarketing reports and electronic health records showing that the safety profile for men treated with the drug is consistent with the safety profile in women treated with this medication.

According to the study, enzyme USP15 may regulate cancer cell response to poly-(ADP-ribose) polymerase inhibitors.

A phase 3 study compared overall survival and cardiac safety between biosimilar trastuzumab (Ontruzant) and the reference medicine.

When combined, treatment with metformin and heme suppressed tumor growth in mice.

Top news of the day from across the health care industry.

Trastuzumab is indicated for the treatment of human epidermal growth factor receptor-2 (HER2) overexpressing breast cancer and HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.

With this approval, atezolizumab plus nab-paclitaxel is the first cancer immunotherapy regimen to be approved for breast cancer.

Atezolizumab (Tecentriq) plus chemotherapy is approved under the FDA’s Accelerated Approval Program, which allows conditional approval of a medicine that fills an unmet medical need for a serious or life-threatening disease or condition.

Patient-driven recommendations to reduce breast cancer-related economic burden could be key to shaping policies and interventions.

Top news of the week from Specialty Pharmacy Times.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

Top news of the day from across the health care landscape.

The new class of smart drugs has the ability to bring the toxic payload directly to the cancer cells.

This study demonstrates the significance and efficacy of breast cancer screenings for prevention and early intervention.

Translational study of breast cancer therapy sought to ‘take research from bench to bedside.’

Ado-trastuzumab emtansine (Kadcyla) is currently approved for the treatment of patients with HER-2 positive metastatic breast cancer who previously received trastuzumab and a taxane.

Researchers have identified a link between CXCR4 expression, fibrosis, and immunosuppression in patients with metastatic breast cancer.

Top news of the day across the health care landscape.

Researchers aimed to better understand the different ways that breast cancer avoids immune system detection.

Study examines whether markers of biological aging due to cancer treatment are related to cognitive function in survivors of breast cancer.